25/06/2024 - 12:51

Radiopharm soars on $70m funding for cancer treatment

25/06/2024 - 12:51


Save articles for future reference.

Radiopharm Theranostics’ stock rocketed up more than 35 per cent this morning after the cancer-fighting firm secured commitments from leading international and Australian institutional investors to raise $70 million at a premium to its most recent share price. The funds will be used to advance the company’s clinical programs for the diagnosis and treatment of cancer through its innovative radiopharmaceutical products.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options